---
title: "\"Performance\" SINOMAB BIO-B's annual loss narrowed to 105 million RMB"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280195009.md"
description: "SINOMAB BIO-B announced its financial results for the fiscal year 2025, reporting a loss of 105 million RMB, compared to a loss of 185 million RMB in the previous year; the loss per share is 0.09 RMB. No final dividend will be distributed. There were no confirmed revenues during the year"
datetime: "2026-03-23T16:44:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280195009.md)
  - [en](https://longbridge.com/en/news/280195009.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280195009.md)
---

# "Performance" SINOMAB BIO-B's annual loss narrowed to 105 million RMB

SINOMAB BIO-B (03681.HK) announced its performance for the fiscal year 2025, reporting a loss of 105 million RMB, compared to a loss of 185 million RMB in the previous year; the loss per share is 0.09 RMB. No final dividend will be distributed. There were no confirmed revenues during the year

### Related Stocks

- [03681.HK](https://longbridge.com/en/quote/03681.HK.md)

## Related News & Research

- [Dr. Shui On Leung Invited to the 2026 LifeArc Translational Science Summit in the UK](https://longbridge.com/en/news/286186365.md)
- [China Telecom's Shares Rise After Becoming Last of Country's Big Three Telcos to Roll Out Token Plans](https://longbridge.com/en/news/286859736.md)
- [Sentia insider sells options worth NOK 1.11 million](https://longbridge.com/en/news/287112930.md)
- [Dream Unlimited Corp. Announces Quarterly Class a Subordinate Voting Share and Class B Common Share Dividend](https://longbridge.com/en/news/287086466.md)
- [Release according to article 135 section 2 BörseG](https://longbridge.com/en/news/286754366.md)